Samra Turajlic The Royal Marsden NHS Foundation Trust, London, UK discusses the second part of A phase II study of Anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell cancer (ADAPTeR) at the Kidney Cancer International Symposium 2019 in Dubrovnik, Croatia
Part 2 – A phase II study of Anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell cancer (ADAPTeR)
